INTRODUCTION
============

Glutathione (GSH) plays a myriad of roles in the body. It is a major cellular antioxidant, involved in defense against oxidative stress and redox signaling. GSH also modulates cell proliferation, apoptosis, immune function, and fibrogenesis ([@B125]). In cancer cells, GSH and enzymes of the mercapturic acid pathway play a role in resistance to many chemotherapeutic drugs. However, not all xenobiotics (including drugs) are conjugated/inactivated by this pathway ([@B26]); some are in fact activated into cytotoxic compounds. This review explores the importance of the mercapturic acid pathway and the potential of intra-tumor activation of old and recently discovered chemotherapeutics. The expression patterns of participating enzymes of the mercapturic acid pathway could theoretically be employed to drive the activation of such compounds within the tumor.

The mercapturic acid pathway (**Figure [1](#F1){ref-type="fig"}**) involves the conjugation of the tripeptide, GSH, to xenobiotics (including drugs) to render them more hydrophilic and facilitate their elimination. Although some spontaneous reactions could occur, the cytosolic glutathione transferases (GST) catalyze the nucleophilic conjugation of GSH with a wide spectrum of electrophiles ([@B7]). Being the first step in the metabolism and eventual removal of the drug from the body, GST is associated with chemotherapeutic resistance since exposure to these drugs is often associated with induction of GST, especially GST P1-1 ([@B30]; [@B75]; [@B83]). The GSH-conjugated compounds generated are then actively pumped out of the cell by numerous members of the MRP/ABCC family, which appear to have broad and partially overlapping substrate specificity ([@B9]). At the cell surface, the first step in the catabolism of GSH-conjugates is catalyzed by the membrane-bound gamma-glutamyl transferase (γGT) which removes the GSH γ-glutamyl group and transfers it to appropriate acceptors. Similar to what has been described for GST, γGT is also considered to be part of a resistance phenotype. The main reason for this is the role that γGT plays in maintaining appropriate GSH levels in the cells for xenobiotic detoxification by conjugation ([@B158]). The newly formed cysteinylglycine *S*-conjugates are further processed by dipeptidases/aminopeptidases to remove the glycyl group and produce cysteine *S*-conjugates. These compounds then re-enter the cell via various transporters including organic anion transport polypeptides and cystine/cysteine importers ([@B87]; [@B15]; [@B43], [@B41]; [@B64]). In the cytosol, *N*-acetyl transferases create mercapturic acid versions of the xenobiotics which are generally more polar and more water soluble than the parental compound. At this point, the compounds are generally non-toxic and excreted from the body through bile or urine. Alternatively, instead of acetylation, some compounds can be converted by cysteine *S*-conjugate β-lyase to produce an unstable and highly reactive thiol.

![**Detoxification of xenobiotic through the mercapturic acid synthesis pathway.** X, xenobiotic; GS-X, GSH-conjugated version of X; CG-X, cysteinylglycyl-X; C-X, cysteinyl-X; NAC-X, mercapturic acid version of X; ^-^S-X, highly reactive thiol version of X; GST, glutathione *S*-transferase, γGT, gamma-glutamyl transferase; Pept., peptidase; Import., peptide transporter or cystine/cysteine importer.](fphar-05-00181-g001){#F1}

There are several examples of drugs becoming toxic/bioactive following their conjugation with GSH. Trichloroethylene is metabolized to form \[*S*-(1,2-dichlorovinyl)GSH\], which is the first step in the GSH metabolism pathway. *In vitro* ([@B115]; [@B20]; [@B29]) and *in vivo* ([@B183]; [@B51]), the downstream metabolites of GSH *S*-dichlorovinyl, such as *N*-acetyl-*S*-(1,2-dichlorvinyl)-[L]{.smallcaps}-cysteine and *S*-(1,2-dichlorovinyl)-[L]{.smallcaps}-cysteine, induce toxicity towards the cells responsible for their production ([@B177]; [@B154]). Consistent with what was observed with trichloroethylene, the GSH-*S*-conjugate of 4-hydroxynonenal (HNE) causes a loss in cell viability in γGT-expressing cells ([@B52]). This effect was attributed to the cysteinylglycine *S*-conjugate of HNE ([@B16]; [@B17]; [@B156]).

The expression of several enzymes involved in the mercapturic acid pathway (notably GST and γGT) is induced in cancer cells and particularly drug resistant cancer cells (**Table [1](#T1){ref-type="table"}**). The specific expression of these enzymes involved in the local production of cytotoxic/bioactive drugs has been exploited to design and develop various types of anticancer prodrugs. This review describes the enzymes involved in drug activation in the order they participate along the mercapturic acid pathway, GST, γGT, and β-lyase. The potential to exploit the induced expression of these enzymes as predictive markers and the opportunity this presents for drug design is discussed.

###### 

Activity and expression levels of glutathione-*S*-transferase and gamma-glutamyl transferase in tumor tissues.

  Tumor             Glutathione *S*-transferase   Gamma-glutamyl transferase                                                   
  ----------------- ----------------------------- ---------------------------- ----------------------------------------------- ----------------------------------
  Liver             ↓ 0.50                        [@B94]                       ++                                              [@B191], [@B81]
                                                                                                                               
                                                                                                                               
                    ↓ Pol. M1, T1                 [@B176]                                                                      
                                                                                                                               
  Kidney            ↓ 0.27--0.44                  [@B36], [@B194]              ++                                              [@B81]
                    ↓ Pol. P1, M1, T1             [@B3]                        ↑ vs. normal tissue (activity)                  [@B6]
                                                                                                                               
  Esophagus         ↑ 5.75                        [@B190]                      \+                                              [@B81]
                    ↓ Expression P1               [@B195]                      ↑ vs. normal tissue (expression and activity)   [@B55]
                                                                                                                               
  Stomach           ↑ 1.36--1.66                  [@B94], [@B155]              ±                                               [@B81]
                                                                                                                               
  Colon             ↑ 1.37--4.3                   [@B190], [@B136]             \+                                              [@B81]
                                                                                                                               
                                                                               ↑ vs. normal tissue (expression and activity)   [@B55], [@B141]
                                                                                                                               
  Pancreas          ↓ Pol. M1, T1                 [@B54]                       \+                                              [@B81], [@B162]
                                                                                                                               
  Lung              ↑ 1.83--2.63                  [@B36], [@B94]               ±                                               [@B81]
                                                                                                                               
                                                                               ↑ vs. normal tissue (expression)                [@B182], [@B35], [@B11]
                                                                                                                               
  Thyroid           ↓ Pol. P1, M1, T1             [@B65], [@B120]              \+                                              [@B81]
                                                                                                                               
  Breast            → 0.85--1.33                  [@B58],[@B94]                ++                                              [@B48], [@B81],
                    ↓ Pol., methyl. P1            [@B170]                      ↑ vs. normal tissue (expression and activity)   [@B55], [@B10]
                                                                                                                               
  Ovary             ↑ Expression                  [@B86]                       \+                                              [@B150], [@B81], [@B80]), [@B69]
                                                                                                                               
  Prostate          ↓ Pol. P1, M1, T1             [@B139], [@B164]             ++                                              [@B81]
                    ↓ Methyl. P1                  [@B53]                       ↑ vs. normal tissue (expression and activity)   [@B55]
                                                                                                                               
  Urinary bladder   ↑ 5.17                        [@B112]                      ↑ vs normal tissue (expression and activity)    [@B55]
                                                                                                                               
                    → Expression                  [@B146]                                                                      

For GST, arrows indicate if the measured activity or expression is increased (↑), decreased (↓) or stable (→) in comparison with normal tissue. Values are the ratio of GST activity in tumor tissue with GST activity in normal tissue. Pol. refers to polymorphism of GST genes responsible for the loss of activity of GST P1 (P1), GST M1 (M1), or GST T1 (T1) isoenzymes. Methyl. refers to DNA methylation in the promoter region of GSTP1 gene responsible for epigenetic silencing of this isoenzyme. For gamma-glutamyl transferase, arrows indicate that the measured activity or expression is increased (↑) in comparison with normal tissue. The signs + and ± indicate the level of γGT expression in tumor tissues measured by immunohistochemistry.

BIOACTIVATION OF CANCER COMPOUNDS BY GST
========================================

Glutathione transferases (EC 2.5.1.18) are a superfamily of dimeric detoxification enzymes which contribute to the cellular biotransformation of electrophilic compounds ([@B129]). They provide protection against genotoxic and carcinogenic effects of numerous substances of both xenobiotic and endogenous origins. The essential role of GST is to catalyze the conjugation of GSH with a wide variety of compounds, including drugs, resulting in the formation of the corresponding GSH-conjugates and subsequently facilitate their clearance from the body. In humans, various isoforms of GST are present in virtually all tissues with the liver exhibiting the highest cytosolic GST activity level followed by kidney, lung, and intestine ([@B147]).

GST AND CANCER
--------------

Although GST detoxifying activity protects cells from endogenous toxic products, it also blunts the effectiveness of certain anticancer drugs ([@B145]). GST and GSH are frequently elevated in many tumors relative to surrounding healthy tissue ([@B94]). Isoenzyme GST P1-1 is notably induced in lung, colon, and stomach cancers and was found to be implicated in cellular resistance to chemotherapeutic agents ([@B30]; [@B75]; [@B83]).

The polymorphism in GSTM1 and GSTT1 genes, leads to complete lack of activity of their corresponding enzymes and is responsible for poor elimination of carcinogenic substances which are potential sources of reactive oxygen species ([@B163]; [@B110]). This polymorphism has been associated with increased risk of benign prostatic hyperplasia and prostate cancer ([@B164]) and can be a useful biomarker to identify patients at higher risk for fatal prostate cancer ([@B1]; [@B121]). In prostate, but also breast, endometrial and hepatocellular carcinomas, another early tumor marker is GSTP1 promoter methylation which is detected at various percentages of clinical samples ([@B53]; [@B205]; [@B18]; [@B117]; [@B200]). The epigenetic silencing of GSTP1 provides a mechanism of resistance which makes tumors with GSTP1 promoter methylation bad candidates for the GST-activated anti-cancer prodrugs presented in this review. However, recent studies demonstrated that it is possible to re-sensitize tumors using a combination of molecules specifically reverting the aberrant DNA methylation in cancer cells (through drugs inhibiting DNA methyltransferase activity) and cytotoxic drugs ([@B157]; [@B22]; [@B167]).

GST ANTICANCER PRODRUGS
-----------------------

An approach to solving drug resistance due to over expression of GST is to design specific GST inhibitors ([@B166]). Alternatively, GST overexpression offers the opportunity to target resistant tumors with GST-activated prodrugs. This type of compound undergoes GST-catalyzed breakdown to release locally cytotoxic metabolites and thereby attenuate off target adverse side effects. Amongst these prodrugs, two categories can be distinguished.

The first category consists of prodrugs containing a GSH or GSH-like structure for which a β-elimination reaction, catalyzed by GST, releases a cytotoxic compound. This includes compounds such as nitrogen mustards, which have the property to alkylate DNA after further transformation: TLK286 (canfosfamide, TELCYTA^TM^) and analogs ([@B126]; [@B169]; [@B46]; **Figure [2A](#F2){ref-type="fig"}**). TLK286 showed interesting *in vitro* and *in vivo* antiproliferative activity on cells with high GST P1-1 expression as a result of selection for doxorubicin, cyclophosphamide, and platinum resistance ([@B137]; [@B187]). In murine xenografts, tumor growth inhibition, or regression in response to TLK286 was positively correlated with the level of GST P1-1 expression ([@B137]). Several clinical trials demonstrated that TLK286 was active and safe to use in combination treatment regimens with standard chemotherapeutic agents, including platinums, taxanes, and anthracyclines. Noteworthy, clinical efficacy was observed with both relapsed patients with ovarian and non-small cell lung cancers, and in the first-line treatment setting in non-small cell lung cancer patients ([@B173]; [@B193]).

![**Mechanisms of activation of GST prodrugs.** TLK286 **(A)** has a GSH-like moiety in its structure, in contrast, all other presented drugs are conjugated with GSH during their process of activation by GST. **(B)** for cAVTP, GS-cAVTP, and 6-MP, R~1~: *cis*-butenone; R~2~: H. For tAVTG, GS-tAVTG and 6-TG, R~1~: *trans*-butenone; R~2~: NH~2~. **(D)** for sulfonamine compounds, R~1~: bombesin or aryl derivatives; R~2~: CN or CF~3~. **(E)** for PABA/NO, R~1~: NMe2; R~2~: 4-carboxy-*N*-methylanilinyl. For JS-K, R~1~: 1-carboxyethyl-4 piperazinyl, R~2~: H.](fphar-05-00181-g002){#F2}

The second category regroups prodrugs non-structurally related to GSH. However, their activation by GST involves the production of an intermediate GSH-conjugate.

1.  In this category, *cis*-6-(2-acetylvinylthio)-purine (cAVTP) and *trans*-6-(2-acetylvinylthio)-guanine (tAVTG) contain active thiopurines (6-mercaptopurine and 6-thioguanine, respectively) liberated intracellularly after GSH-conjugation catalyzed by GST M1-1, M2-2, and A4-4, but not GST P1-1 ([@B73]; [@B49]; **Figure [2B](#F2){ref-type="fig"}**). Both compounds exhibited a remarkable growth-inhibitory activity towards leukemic and melanoma cells ([@B72]). *In vivo*, on the contrary to what was observed following the administration of bioactive end products (6-mercaptopurine and 6-thioguanine), no reduction of circulating white blood cells was observed upon administration of cAVTP and tAVTG ([@B73]).

2.  Using a similar strategy, exocyclic enones displaying antitumor activity were produced by a GSH-dependent reaction catalyzed by GST ([@B76], [@B77]). COMC-6 (2-crotonyloxymethyl-2-cyclohexenone) is a potent antitumor agent against both murine and human tumors in culture and in tumor-bearing mice ([@B2]).

3.  Diarylsulfonylureas are a class of antitumor agent with interesting therapeutic efficacy against a wide range of cancers ([@B93]; [@B134]). Sulofenur \[(*N*-(5-indanesulfonyl)-*N*′-(4-chlorophenyl)urea, LY18664\], the prototypic member of this class (**Figure [2C](#F2){ref-type="fig"}**), was evaluated in clinical trials on a variety of patients with kidney ([@B128]), ovary ([@B144]), breast ([@B181]), lung ([@B140]), and stomach ([@B102]) cancers. It appeared that sulofenur can undergo metabolic biotransformation to yield the GSH-conjugate of *p*-chlorophenyl isocyanate \[*S*-(*N*-*p*-chlorophenylcarbamoyl) GSH, SCPG; [@B100]\]. Whether a direct involvement of GST is necessary or not in the production of this GSH-conjugate remains unclear. However, it was clearly demonstrated that SCPG is further processed through the mercapturic acid pathway to the corresponding N-acetylcysteine conjugate \[*N*-acetyl-*S*-(*p*-chlorophenylcarbamoyl)cysteine, NACC\], which possesses comparable anticancer activity to the parent compound. The GSH- and cysteine-conjugates produced are susceptible to thiol exchange reactions and may act as carbamoylating agents towards biomacromolecules ([@B33]; [@B70]). NACC, whose mechanism of action remains unclear, demonstrated selective anticancer activity, and low toxicity, which make NACC and its analogs promising anticancer agents ([@B21]).

4.  Another approach was to use the sulphonamidase activity of GST. GST catalyzes the GSH-mediated hydrolysis of sulfonamide bonds, releasing GST competitive inhibitors such as benzylsulfonyl-GSH or *S*-benzyl-GSH ([@B107]; [@B204]; [@B8]; **Figure [2D](#F2){ref-type="fig"}**).

5.  Finally, electrophilic diazenium diolates were designed as prodrugs for spontaneous nitric oxide (NO) release at physiological pH, after a reaction with GSH catalyzed by GST. Essentially two compounds were studied. PABA/NO \[(*O*^2^-(2,4-dinitro-5-(*N*-methyl-*N*-4 carboxyphenylamino)phenyl) 1-*N*,*N*-dimethylamino)diazen-1-ium-1,2-diolate; [@B56]\] and JS-K \[*O*^2^-(2,4-dinitrophenyl) 1-\[(4-ethoxycarbonyl) piperazin-1-yl\]diazen-1-ium-1,2-diolate; [@B174]\] were selectively activated by GST M1 and GST A1, respectively, and produced abundant NO in the tumor and contributed to chemotherapy by GSH consumption, DNA synthesis inhibition and inhibition of enzymes responsible for cellular damage repair (**Figure [2E](#F2){ref-type="fig"}**). PABA/NO and JS-K demonstrated antitumor activity in mice bearing human ovarian carcinoma ([@B56]) and prostate carcinoma ([@B114]) or multiple myeloma ([@B105]), respectively. Recently, new generations of more stable and potent GST-activated NO prodrugs have been developed ([@B122]; [@B60]).

GLUTATHIONE *S*-DERIVATIVES ACTIVATED BY γGT AND PEPTIDASES
===========================================================

Gamma-glutamyl transferase (EC2.3.2.2) catalyzes the transpeptidation and hydrolysis of the γ-glutamyl group of GSH and related compounds to an acceptor molecule, including water, amino acids, and peptides. It is found on the plasma membrane, facing extracellularly, playing an essential role in the maintenance of intracellular cysteine ([@B138]). Considering GSH's important role as a cellular antioxidant, γGT has traditionally been considered a component of the cell's oxidative stress defenses. However, the range of γGT substrates has expanded considerably, now including a range of GSH conjugates, leukotriene C4 (LTC4), *S*-nitroso-GSH and GSH adducts of xenobiotics, suggesting diverse roles for γGT.

High expression of γGT is commonly found on cells involved in transport, on the luminal surface of secretory and absorptive cells. Its highest expression is on the luminal surface of the proximal tubules in the kidney, whilst the bile ducts, bile canaliculi, and endothelial cells of the nervous system capillaries also have high expression ([@B175]; [@B79]).

Oxidative stress has been shown to induce γGT expression ([@B109]; [@B106]; [@B124]; [@B12]; [@B165]). High γGT expression protects melanoma cells from hydrogen peroxide or ascorbic acid induced oxidative stress ([@B68]). It also allows the cells to maintain their intracellular GSH levels and subsequently respond to oxidative stress. Conversely, γGT has been demonstrated to have pro-oxidant effects. Combined with metal ions (iron or copper), γGT can induce lipid peroxidation ([\#XBR176](#XBR176), [\#XBR176](#XBR176); [@B178]). γGT has been linked to reactive oxygen species generation in cells ([@B47]; [@B34]; [@B149]).

γGT AND CANCER
--------------

Gamma-glutamyl transferases expression has been shown to be increased in numerous cancers. Increased levels have been observed in cancer of the ovary, liver, lung, and breast, and in melanoma and leukemia ([@B61]; [@B66]; [@B35]; [@B10]; [@B28]; [@B130]). In many cases the γGT levels are higher in the corresponding primary tumor ([@B127]). An extensive study by [@B81] scored the expression of γGT in a variety of tumors. Carcinomas in particular express γGT, with carcinomas of the kidney, liver, and prostate showing strong expression ([@B81]). Furthermore, some carcinomas of the breast, ovary, uterus, and pancreas were shown to express γGT. On the contrary, non-epithelial malignancies and sarcomas rarely expressed γGT.

Gamma-glutamyl transferases has been considered an early marker of neoplastic transformation. Many early studies have demonstrated in *in vivo* models the appearance of γGT expression in areas previously negative following exposure to carcinogens ([@B158]). The underlying mechanism of this phenomenon remains unclear. A genome-wide analysis of pancreatic cancer implicated GGT1 as playing a role in carcinogenesis ([@B38]). The proto-oncogene KRAS was shown to be involved in the upregulation of γGT expression. Recently, [@B135] have demonstrated that KRAS transformed prostate epithelial cells are more resistant to hydrogen peroxide induced free-radicals than non-transformed cells. They observed an upregulation of GGT2 in the KRAS transfected cells and confirmed its role in resistance to hydrogen peroxide treatment. This has also been observed in colon carcinoma cells where radiation induced γGT activity was mediated through Ras pathway ([@B148]).

The early appearance of γGT in neoplasms suggests the potential for γGT to play a role in tumor progression. γGT has been shown to give cells a growth advantage *in vitro* and *in vivo*. High expression of γGT provides cells with greater quantities of cysteine through the breakdown of extracellular GSH ([@B66]; [@B78]; [@B89]). This explains the difference in growth rates of cells when moved from the *in vitro* setting to mice, where extracellular GSH and cysteine is limited *in vivo*. In clones of melanoma cells, the extent of γGT expression was shown to be proportional to the invasive ability of the clone ([@B180]).

γGT AND DRUG RESISTANCE
-----------------------

Beyond its differential expression in cancer, γGT is considered to be part of a resistance phenotype ([@B158]). The main reason for this is the role that γGT plays in maintaining GSH levels within the cell. GSH plays an important part in the detoxification of xenobiotics by binding to a range of agents and this allows for GSH mediated expulsion of these compounds from the cell.

The relationship between γGT and chemotherapy resistance is demonstrated by a number of experiments showing that transfection with γGT both *in vitro* and *in vivo* leads to resistance to members of the platinum drug family, and in particular to *cisplatin* ([@B82]; [@B32]; [@B59]). Further evidence of the relationship comes from biopsies from ovarian adenocarcinoma patients before and after treatment (cisplatin, chlorambucil, and 5FU). Cells grown from biopsies taken before and after treatment, showed a 6.5-fold increase in γGT activity following treatment ([@B119]). However, [@B171] found no direct link between γGT and resistance, despite an evident growth advantage for γGT overexpressing cells.

Another proposed mechanism for platinum drug resistance is the formation of adducts between the platinum drug and the cysteinyl-glycine product of γGT. These complexes have poor ability to cross the cell membrane; as a result the platinum drug rarely reaches its target (DNA). These adducts have been described in the extracellular media of γGT overexpressing cells and the plasma of patients treated with oxaliplatin ([@B32], [@B31]; [@B151]; [@B99];[@B28]).

Gamma-glutamyl transferases has also been implicated in resistance to radiation therapy. In lymphoid cells, γGT plays a role in maintaining the intracellular GSH levels that are essential for protection against radiation ([@B98]). Inhibition of γGT in melanoma cells significantly increased the radiosensitivity of a high γGT variant ([@B161]). In CC531, a colon cancer cell line, γGT was upregulated in a time and dose-dependent manner to irradiation. This increase in γGT activity was attributed to *de novo* synthesis of the mRNA. It was further demonstrated that signaling through the Ras pathway was responsible for this increase ([@B148]).

HIGH γGT EXPRESSION AND INTRATUMOR DRUG ACTIVATION
--------------------------------------------------

The high expression of γGT within aggressive and drug-resistant tumors implies that GSH-conjugated prodrugs, activated at the cell surface by γGT, should be particularly effective against γGT-positive tumors. The metabolism of these compounds by γGT positive tumor cells should produce high local concentrations of bioactive and membrane permeable metabolites that would then block tumor cell proliferation and eventually tumor growth. Increasing the concentration of active metabolites at the tumor site, will subsequently limit the concentration of active drug at other sites, reducing side effects.

### Arsenic-based GSH-conjugates

GSAO \[4-(*N*-(*S*-glutathionylacetyl)amino)phenylarsonous acid\] and Darinaparsin (ZIO-101; *S*-dimethylarsino-GSH) are arsenic-based GSH-conjugates with demonstrated antitumor activity evaluated in clinical trials ([@B44]; [@B40]; [@B37]; [@B188]; [@B92]; [@B91]). For both drugs, extracellular γGT activity is an essential and limiting step in their activation into membrane permeable compounds ([@B43]; [@B64]). Indeed, it has recently been demonstrated that tumor γGT could be used for therapeutic delivery ([@B162]).

***GSAO.*** 4-(*N*-(*S*-glutathionylacetyl)amino)phenylarsonous acid is a prospective cancer drug and has just completed a phase I dose escalation study in patients with solid tumors refractory to standard therapy ([@B91]). Treatment was very well tolerated. Of 34 patients, 20 were evaluated for response (receiving two or more cycles of GSAO). Whilst no patient exhibited an objective response, eight had stable disease, with one patient having stable disease for 18 weeks.

4-(*N*-(*S*-glutathionylacetyl)amino)phenylarsonous acid consists of a phenylarsenoxide moiety attached by an *N*-acetyl linker to the cysteine thiol of reduced GSH (**Figure [3](#F3){ref-type="fig"}**). The phenylarsenoxide group is the active moiety, imparting to GSAO its activity by crosslinking closely spaced protein thiols and forming a high affinity ring structure between its arsenic and the thiols ([@B45]). GSAO specifically targets proliferative endothelial cells, which consequently starves the tumor of the nutrients required to support its expanding growth ([@B44]; [@B40]). The GSH moiety contributes to the transport of GSAO in and out of the cell ([@B43], [@B40]).

![**Activation process of GSAO and subsequent activity on endothelial cell proliferation. (A)** GSAO activation by γGT and peptidase. **(B)** Pancreatic tumor cell γGT activity positively correlates with GSAO-mediated proliferation arrest of endothelial cells in a transwell model. Pancreatic adenocarcinoma cells are represented by circles and normal and tumor-activated pancreatic stellate cells by squares. BxPC-3 pancreatic tumor cells transfected with γGT are represented as triangles. **(C)** Model of GSAO activation by tumor γGT (from [@B162]).](fphar-05-00181-g003){#F3}

4-(*N*-(*S*-glutathionylacetyl)amino)phenylarsonous acid in its original form is essentially membrane impermeable. Upon reaching the cell surface the γ-glutamyl group is cleaved by γGT ([@B43]), generating the dipeptide form, 4-(*N*-(*S*-cysteinylglycylacetyl) amino) phenylarsonous acid (GCAO). GCAO is then able to enter the cell through organic anion transporters (OATPs). Within the cell further processing by dipeptidases likely occurs, resulting in the formation of the single amino acid form of GSAO, 4-(*N*-(*S*-cysteinylacetyl)amino)phenylarsonous acid (CAO; [@B43]; **Figure [3A](#F3){ref-type="fig"}**).

The phenylarsenoxide moiety of CAO has been confirmed to crosslink the cysteine residues 57 and 257 of the adenosine nucleotide translocator (ANT; [@B152]). ANT is the most abundant protein found on the inner mitochondrial membrane and it is responsible for the exchange of matrix ATP for cytosolic ADP across the inner mitochondrial membrane. Disruption of its function has been shown to have major impacts on mitochondrial integrity and cell survival ([@B74]; [@B132]; [@B44]). The calcium-dependent binding of CAO to ANT induces a conformational change ([@B74]) which results in the opening of the mitochondrial permeability transition pore (MPTP) and allows the equilibration of small solutes and the release of pro-apoptotic proteins from the intermembrane space. The equilibration that results leads to a collapse of the proton-motive force across the membrane and a colloid osmotic pressure that causes massive swelling of the mitochondria ([@B132]).

There are a number of factors that influence GSAO activity: the level of expression of the enzyme responsible for its activation (γGT); intracellular GSH levels; and the expression of the multi-drug resistance association proteins, ABCC1 (MRP1) and ABCC2 (MRP2). The combination of low intracellular GSH levels and low expression of ABCC1 and ABCC2 in proliferative endothelial cells accounts for GSAO selectivity and subsequently for GSAO anti-angiogenic properties ([@B39],[@B40]; [@B153]).

Pancreatic tumors display the most prominent stromal/desmoplastic reaction of all epithelial tumors ([@B5]). Knowing that pancreatic tumorigenesis has been associated with expression of γGT by both cancer and tumor-associated stellate cells ([@B162]), [@B162] have explored the utility of this enzyme in delivering GSAO to pancreatic ductal adenocarcinoma. They demonstrated that human pancreatic tumor and stellate cells activate/process GSAO into its active metabolite and that γGT activity positively correlates with GSAO-mediated proliferation arrest of co-cultured endothelial cells (**Figure [3B](#F3){ref-type="fig"}**). Importantly, tumor γGT activity positively correlates with GSAO-mediated inhibition of pancreatic tumor angiogenesis and tumor growth in mice.

4-(*N*-(*S*-penicillaminylacetyl)-amino)phenylarsonous acid (PENAO), a cysteine mimetic analog of the cysteine-*S*-conjugate metabolite of GSAO has been investigated. In this compound, penicillamine replaces the cysteine moiety of CAO. PENAO was shown to have the same molecular target as GSAO ([@B41]; [@B152]). By bypassing the cell surface processing of GSAO, PENAO accumulated 85 times faster in cells ([@B41]). This corresponds to an increase in anti-proliferative capacity on a variety of endothelial and cancer cell lines. Interestingly, PENAO has a strong anti-proliferative activity against glioblastoma cell lines ([@B24]) and primary isolates of diffuse intrinsic pontine glioma ([@B189]). *In vivo*, PENAO demonstrated preclinical activity without signs of toxicity in tumor models of glioblastoma ([@B23]) and pancreatic carcinoma ([@B41]). In the later model, PENAO was approximately 20-fold more efficacious than GSAO ([@B41]). Large scale animal toxicity studies demonstrated that PENAO was as well tolerated as GSAO, suggesting an interesting therapeutic window for this compound. PENAO is currently being tested in a clinical Phase I trial in patient with solid tumors refractory to standard chemotherapy. PENAO is another example of a mercapturic acid pathway metabolite with antitumor properties. However, the lack of processing by γGT removes the targeting advantage presented by GSAO.

***Darinaparsin.*** *S*-dimethylarsino-GSH (Darinaparsin; ZIO-101) is an organic arsenical compound currently in clinical development. It has been tested in Human with hematologic malignancies ([@B92]; [@B142]) as well as solid tumors ([@B188]; [@B199]). Significantly more potent and better tolerated than arsenic trioxide, Darinaparsin showed encouraging responses in T-cell lymphoma ([@B92]) and AML ([@B142]) patients. However, in a phase II evaluation of the compound in hepatocellular carcinoma, no objective response was shown ([@B199]).

Darinaparsin belongs to the class of organic arsenical compounds that are generally considered less toxic than inorganic ones ([@B196]; [@B42]). It was synthesized by conjugating GSH to dimethyl arsenic (**Figure [4](#F4){ref-type="fig"}**). Darinaparsin shares some characteristics with other arsenicals but has also unique properties. As do other arsenicals, it induces G~2~/M cell cycle arrest and triggers apoptosis through disruption of mitochondrial functions and JNK activation and is responsible for reactive oxygen species production ([@B37]). However, unlike arsenic trioxide, GSAO ([@B40]) or PENAO ([@B41]), Darinaparsin activity is unaffected by the expression of ABCC1 (MRP-1), modulation of GSH levels ([@B37]) and heme-oxygenase inhibition ([@B63]).

![**Activation process of Darinaparsin**.](fphar-05-00181-g004){#F4}

Darinaparsin was characterized *in vitro* as a potent inducer of growth arrest and apoptosis in a range of hematologic malignancies such as acute promyelocytic leukemia (APL), acute lymphoblastic leukemia, B cell lymphoma, and multiple myeloma ([@B37]; [@B131]). In contrast to arsenic trioxide ([@B113]) and like PENAO and melarsoprol ([@B19]), Darinaparsin, at concentrations that induce apoptosis, does not induce PML/RAR degradation in APL cells. In the context of solid cancer, Darinaparsin was found to have preferential cytotoxic and radiosensitizing effects as compared with normal cells both *in vitro* and in a clinically relevant model ([@B185], [@B184]).

It was recently demonstrated that Darinaparsin, which is essentially a GSH *S*-conjugate of dimethylarsenic, needs to be processed at the cell surface before exerting its activity on various cancer cells. The GSH moiety of the drug has to be processed by γGT before further processing by dipeptidases to generate dimethylarsino-cysteine (DMAC), a cysteine *S*-conjugate which is imported via cystine transporters ([@B64]; **Figure [4](#F4){ref-type="fig"}**). Whether DMAC could be subsequently transformed intracellularly into (i) a highly reactive and cytotoxic thiol through β-lyase activity or (ii) dimethylarsenite/dimethylarsenate is not known. Similarly to what was observed in the case of GSAO and CAO ([@B43]), [@B64] demonstrated that DMAC recapitulates the effects of Darinaparsin and that γGT is the first and limiting step in the activation of the drug. They also linked Darinaparsin efficacy to the level of expression of cystine/cysteine importing systems in cancer cells.

### S-nitrosoglutathione

*S*-nitrosoglutathione (GSNO) is the *S*-nitrosated derivative of GSH and is thought to be a critical mediator of the downstream signaling effects of NO ([@B14]). GSNO plays roles as a carrier for NO and in protein *S*-nitrosation or *S*-glutathiolation ([@B14]). GSNO can be cleaved by γGT ([@B90]; [@B4]; [@B13]), generating *S*-nitrosocysteinylglycine and releasing NO *in vitro*. GSNO has been tested in a number of clinical trials, the majority focusing on the cardiovascular effects of GSNO as a NO donor ([@B14]). As do other NO-donating compounds, GSNO induces oxidative stress and initiates apoptosis ([@B192]). GSNO promotes NO-induced apoptosis in colon carcinoma cell lines through depletion of intracellular GSH and the release of NO, ([@B88]; [@B123]). In a variety of cell lines, GSNO treatment combined with a MEK inhibitor was shown to inhibit the proliferation and invasive phenotype of the cells ([@B62]). In T and B lymphocytes the anti-proliferative effect of GSNO was dependent on γGT activity ([@B85]). The anti-proliferative activity of GSNO, combined with the overexpression of γGT in tumor cells, suggests the possibility of its utility in cancer therapy. This requires further understanding of the roles that NO plays in cancer.

In the light of the promising results obtained, notably with the arsenical-based GSH-conjugates, it appears that tumor γGT could potentially be employed in drug targeting and delivery. In addition to cleavage of the γ-glutamyl from a GSH moiety, γGT can also catalyze the cleavage of γ-glutamyl moieties from a variety of compounds. This property along with tissue/tumor expression of γGT was used to develop γ-glutamyl prodrugs.

### γ-glutamyl conjugates and *N* acetyl γ-glutamyl conjugates

Due to the tissue distribution of γGT, γ-glutamyl prodrugs have been mostly developed for kidney applications. An anti-nociceptive prodrug, γ-glutamyl-dermorphin, was explored by comparing the pain threshold of mice ([@B133]). More extensively investigated was the γ-glutamyl conjugate of [L]{.smallcaps}-DOPA (dihydroxyphenylalanine). This prodrug provides the precursor of dopamine, DOPA, upon activation and was explored as a potential renal vasodilator ([@B197]; [@B198]; [@B168]). Clinical testing of the prodrug determined that despite reasonable kidney specificity it had low bioavailability ([@B118]). A number of other compounds were conjugated to a glutamyl group and tested; however none were approved for use ([@B95]).

In terms of potential antitumor activity, γ-glutamyl-protected *N*-hydroxyguanidines (NHGs) have been developed to explore the ability to deliver NO to the kidney (**Figure [5A](#F5){ref-type="fig"}**). The NHGs include *N^w^*-hydroxy-[L]{.smallcaps}-arginine, which is an intermediate in the NO synthase synthesis of NO ([@B203]). Whilst promising results were seen, there was a propensity for the potential compounds to cyclize ([@B202],[@B203]) suggesting that NHG conjugation to GSH may be more stable. ([@B202]). As described above for PABA/NO, JS-K, and GSNO, the NHGs, in accordance with γGT expression patterns, contribute to chemotherapy by producing locally high levels of NO which can rapidly react with O~2~^⋅^- to generate the potent oxidant peroxynitrite that, in turn causes extensive cellular damage, including the nitration of protein tyrosine residues ([@B104]).

![**γ-glutamyl conjugates and β-lyase substrates.** Activation of *N*-hydroxyguanidines **(A)** and glutamylated phenolic amines **(B)** by γGT. **(C)** examples of cysteine- and selenocysteine-conjugates activated by β-elimination catalyzed by β-lyase.](fphar-05-00181-g005){#F5}

Glutamylated phenolic amine compounds have been shown to be activated by γGT (**Figure [5B](#F5){ref-type="fig"}**). γ-[L]{.smallcaps}-glutaminyl-4-hydroxybenzene and γ-[L]{.smallcaps}-glutaminyl-4-iodobenzene have been demonstrated to be activated by tyrosinase ([@B159]) and γGT ([@B160]). Both compounds were shown to have greater cytotoxicity in melanoma cell lines when γGT activity was not inhibited ([@B160]).

### γGT-activated prodrugs and potential nephrotoxicity

Gamma-glutamyl transferase being the initial and limiting step in γGT-activated prodrugs processing and because γGT is highly expressed on the luminal surface of the proximal tubules in the kidney, potential nephrotoxicity could have been a limitation in the usage of this class of compound when administered systematically. In the case of GSAO, a reversible renal toxicity described in preclinical studies at the maximal tolerated dose was not observed in human during clinical Phase I ([@B91]). Similarly, Darinaparsin, when employed in patients ([@B188]; [@B199]; [@B92]) didn't display any toxicity profile related to renal dysfunction at dose-limiting toxicity (DLT). Taken together, these clinical studies indicate that the γGT-activated prodrugs have not necessarily nephrotoxic properties. This type of adverse effects is most likely dependent on the nature of the metabolites produced by the mercapturic acid pathway and particularly if the end products are substrates for cysteine conjugate β-lyases. This enzyme is notably responsible for the nephrotoxicity of cisplatin (see below). However, recent studies demonstrated that the modulation of renal GSH content could prevent such toxicity ([@B57]; [@B172]; [@B67]).

β-LYASE AND GENERATION OF CYTOTOXIC PRODUCTS
============================================

Cysteine conjugates produced by dipeptidases or amino peptidases following the GST and γGT steps, are transformed by cysteine conjugate β-lyases present in the cytosol and mitochondria. The β-lyases catalyze the β-elimination of various [L]{.smallcaps}-cysteine *S*-conjugates to the corresponding thiols ([@B27]). The thiols released can be either toxic or pharmacologically active for the cells responsible for their production ([@B26]). Due to the high expression of cysteine conjugate β-lyase in the proximal tubule of the kidney, administration of cysteine-*S*-conjugates of haloalkenes to rodents results in selective nephrotoxicity ([@B179]; [@B84]).

The specific localization along with intense expression of these enzymes in renal carcinoma has led to the design of kidney-selective prodrugs that bypass earlier steps of the mercapturic acid pathway (GST, γGT, and peptidase): these compounds include *S*-(guanin-6-yl)-[L]{.smallcaps}-cysteine ([@B50]), *S*-(6-Purinyl)-[L]{.smallcaps}-cysteine ([@B96]; [@B116]) and selenocysteine-conjugates ([@B25]; **Figure [5C](#F5){ref-type="fig"}**). The potential of these types of compounds as kidney-selective antitumor prodrugs has been demonstrated in tissue distribution experiments. However, because of a lower ratio of kidney/liver β-lyase activity in human than rodents, kidney selectivity remains to be confirmed.

Cisplatin is one of the most effective anticancer agents in the treatment of solid tumors, including, breast, testicular, and ovarian cancer. The drug binds DNA, which is toxic to dividing tumor cells. However, therapy with cisplatin is notably limited by a toxicity mechanism in the non-dividing proximal tubule cells of the kidney that is distinct from DNA cross-linking. It was demonstrated that cysteine *S*-conjugate β-lyase highly expressed in the kidney was responsible for the observed nephrotoxicity ([@B201]; [@B186]). Even if cysteine *S*-conjugate β-lyase is responsible for the synthesis of the highly reactive and cytotoxic thiol version of cisplatin (**Figure [1](#F1){ref-type="fig"}**), the activation of cisplatin into a nephrotoxin relies on the three previous steps of the classical mercapturic acid pathway involving GSTs (GSH conjugation), γGT (production of CisPt-cys-glu) and dipeptidase (production of CisPt-cys; **Figure [5C](#F5){ref-type="fig"}**). Indeed, the inhibition of γGT or cysteine *S*-conjugate β-lyase (both highly expressed in proximal tubule cells of the kidney) blocks the nephrotoxicity of cisplatin in mice ([@B186]). In this process, the action of γGT is a key and limiting step as it transformed the essentially membrane impermeable CisPt-GSH into a membrane permeable CisPt-cys-glu that can be taken up by the cells.

CONCLUSION
==========

The traditional approach to identify potential cancer therapies has been to identify a drug that helps the greatest number of patients. In doing this, the potential of therapies that have a significant impact on a small subset is lost within the larger sample population. The current trend to target specific abnormalities in cancer allows for the development of predictive markers and companion tests to identify which patients have a particular tumor characteristic. From this stems the ability to identify the patient population that will (or will not) respond to the drug. Developing new therapies with the target population in mind will facilitate the development of drugs that will induce a greater tumor response for individual patients. For this to occur, a marker that predicts patient response to the drug is essential.

This review recapitulates the different drug strategies involving GSH-conjugates, and the enzymes of the mercapturic acid pathway, employed over the last twenty years. Amongst the long list of compounds investigated, a limited number of GSH-conjugates have recently progressed towards clinical trials for the treatment of cancer patients. Both GST-activated nitrogen mustard (TLK286) and γGT-activated arsenic-based (GSAO and Darinaparsin) prodrugs have displayed promising activities along with safe profiles.

Given the complexity of mechanisms involved in drug resistance and survival pathways of tumor cells, combination strategies of GSH-conjugates with conventional chemotherapy or targeted drugs should provide very interesting perspectives for the treatment of drug resistant tumors. This approach has already been explored successfully with TLK286 when combined with pegylated liposomal doxorubicin ([@B103]; [@B193]) or with carboplatin plus paclitaxel ([@B173]). Moreover, knowing that the combinations of arsenic trioxide with targeted drugs such as mTOR ([@B71]; [@B97]), EGFR ([@B143]; [@B108]), or proteasome inhibitors ([@B101]) demonstrate potent profiles on a variety of malignancies, it would be of great interest to investigate the antitumor properties of such inhibitors in combination with the arsenical-based GSH-conjugates GSAO and Darinaparsin.

Increased GST and/or γGT tumor expression, generally considered as a bad prognosis marker (associated with drug resistance and disease progression), and could potentially be used as a predictive marker, allowing doctors, after biopsy, to identify which patients will respond best to GST or γGT-activated prodrugs. Predictive biomarkers provide a number of benefits, including: reduced unnecessary treatment; reduced quantity of adverse events; reduced drug attrition rates; improved therapeutic benefit; and better control of medical costs ([@B111]). Whilst taking the time to test for GST and/or γGT tumor expression may slightly delay treatment, it will ensure that GSH-conjugates anticancer prodrugs will be administered to the patients that are more likely to respond.
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6-MP

:   6-mercaptopurine

6-TG

:   6-thioguanine (6-mercaptopurine and 6-thioguanine)

CAO

:   4-\[N-(S-cysteinylacetyl)amino\]phenylarsonous acid

cAVTP

:   cis-6-(2-acetylvinylthio)-purine

CPIC

:   p-chlorophenyl isocyanate

DMAC

:   dimethylarsino-cysteine

DMACG

:   dimethylarsino-cysteinylglycine

EGFR

:   epidermal growth factor receptor

GSH

:   glutathione

GCAO

:   4-\[N-(S-cysteinylglycylacetyl) amino\] phenylarsonous acid

γGT

:   gamma-glutamyl transferase

GSAO

:   \[4-(N-(S-glutathionylacetyl) amino)phenylarsonous acid\]

GS-cAVTP

:   glutathione s-cis-6-(2-acetylvinylthio)-purine

Glu

:   glutamate

Gly

:   glycine

GS-tAVTG

:   glutathione s-trans-6-(2-acetylvinylthio)-guanine

PENAO

:   4-(N-(S-penicillaminylacetyl)-amino)phenylarsonous acid

SCPG

:   S-(N-pchlorophenylcarbamoyl) glutathione

tAVTG

:   trans-6-(2-acetylvinylthio)-guanine.
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